Detalhe da pesquisa
1.
A drug-drug interaction study with letermovir and acyclovir in healthy participants.
Br J Clin Pharmacol;
89(5): 1690-1694, 2023 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36537620
2.
Evaluation of the inhibitory effects of itraconazole on letermovir.
Br J Clin Pharmacol;
89(7): 2122-2130, 2023 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36717270
3.
A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Cathepsin K inhibitor.
J Pharmacokinet Pharmacodyn;
47(5): 473-484, 2020 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32647957
4.
Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
Br J Clin Pharmacol;
85(6): 1072-1083, 2019 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30663085
5.
Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
J Clin Psychopharmacol;
36(4): 314-23, 2016 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27253658
6.
In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans.
Xenobiotica;
46(10): 882-95, 2016 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26864332
7.
Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients.
Pediatr Infect Dis J;
43(3): 203-208, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38241643
8.
Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological-based pharmacokinetic modeling.
Clin Transl Sci;
16(6): 1039-1048, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37085998
9.
Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single- and Multiple-Dose Administration in Healthy Japanese Subjects.
Clin Pharmacol Drug Dev;
11(8): 938-948, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35238179
10.
Assessment of Pharmacokinetic Interaction Between Gefapixant (MK-7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin.
Clin Pharmacol Drug Dev;
11(3): 406-412, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34821075
11.
Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics.
Clin Pharmacol Ther;
111(3): 664-675, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34888851
12.
Drug-Drug Interaction of Letermovir and Atorvastatin in Healthy Participants.
Clin Pharmacol Drug Dev;
11(4): 420-428, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35157785
13.
Absorption, Metabolism, Distribution, and Excretion of Letermovir.
Curr Drug Metab;
22(10): 784-794, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33622223
14.
Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants.
Clin Pharmacol Drug Dev;
10(2): 198-206, 2021 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32700459
15.
Population Pharmacokinetic Analysis of the Cathepsin K Inhibitor Odanacatib: Insights Into Intrinsic and Extrinsic Factor Effects on Exposure in Postmenopausal and Elderly Women.
J Clin Pharmacol;
60(8): 1107-1123, 2020 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32302427
16.
A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants.
Clin Pharmacol;
12: 1-11, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32104104
17.
Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects.
Br J Clin Pharmacol;
67(2): 180-90, 2009 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19094161
18.
Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies.
J Clin Pharmacol;
59(9): 1236-1243, 2019 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31022310
19.
Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Clin Drug Investig;
39(5): 441-451, 2019 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30810914
20.
Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Clin Drug Investig;
39(5): 453-454, 2019 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30895461